A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

NCT02431247 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

725

Enrollment

INDUSTRY

Sponsor class

Conditions

Immunodeficiency Virus Type 1, Human

Interventions

DRUG: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC
DRUG: DRV/COBI FDC
DRUG: FTC/TDF FDC
DRUG: D/C/F/TAF FDC - Matching Placebo
DRUG: FTC/TDF FDC Matching Placebo
DRUG: DRV/COBI FDC Matching Placebo

Sponsor

Janssen Sciences Ireland UC